ASMBAssembly Biosciences, Inc.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great Choice Does Assembly Biosciences (ASMB) have what it takes to be a top stock pick for momentum investors? Let's find out. | ||
 Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 40.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. | ||
 Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +71.43% and +45.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.88% and +9.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||